Sign in

    Alexa Deemer • Cantor Fitzgerald

    Alexa Deemer's questions to Trevi Therapeutics Inc (TRVI) leadership

    Alexa Deemer's questions to Trevi Therapeutics Inc (TRVI) leadership • Q2 2025

    Question

    Alexa Deemer from Cantor Fitzgerald asked which dose or doses from the CORAL trial the company plans to advance into the Phase 3 study for IPF cough.

    Answer

    James Cassella, Chief Development Officer, identified the 54mg BID dose as a "sweet spot" due to its strong performance across both primary and secondary endpoints. He confirmed that the 54mg BID dose will be a key dose taken forward into the Phase 3 program, subject to FDA alignment.

    Ask Fintool Equity Research AI

    Alexa Deemer's questions to ARS Pharmaceuticals Inc (SPRY) leadership

    Alexa Deemer's questions to ARS Pharmaceuticals Inc (SPRY) leadership • Q4 2024

    Question

    Alexa Deemer from Cantor Fitzgerald asked about the breakdown of the epinephrine market between direct-to-patient retail sales and sales to institutional entities like airlines and schools.

    Answer

    Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, clarified that nearly all current neffy sales are through the retail channel. They noted that the institutional market, such as airlines and restaurants, represents a future growth opportunity not yet included in forecasts, with some entities waiting for the 1mg dose to become available before adoption.

    Ask Fintool Equity Research AI